Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03289910 · OUTCOME

Duration of Disease-free Survival

Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia · Source last updated 2026-06-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
days
Interval / dispersion
95% Confidence Interval
Time frame
Up to 7 months

What was measured

Disease-free survival is defined as participants who are still alive and without disease at study completion. Study completion was either death or completion of all protocol-specified activities, whichever came first.

Groups in this outcome

Arm A (Veliparib, Topotecan Hydrochloride, Carboplatin)

Patients receive veliparib PO BID on days 1-21 and topotecan hydrochloride IV continuously over 24 hours and carboplatin IV continuously over 24 hours on days 3-7. Treatment repeats every 28-63 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.

Arm B (Topotecan Hydrochloride, Carboplatin)

Patients receive topotecan hydrochloride IV continuously over 24 hours and carboplatin IV continuously over 24 hours on days 1-5. Treatment repeats every 28-63 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Arm A (Veliparib, Topotecan Hydrochloride, Carboplatin)16
Arm B (Topotecan Hydrochloride, Carboplatin)9

Reported measurements

Source class 1
Values in days · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Arm A (Veliparib, Topotecan Hydrochloride, Carboplatin)120Not reported37137Not reported
Arm B (Topotecan Hydrochloride, Carboplatin)89Not reported27137Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        37
        upper Limit
        137
        value
        120
      2. group Id
        OG001
        lower Limit
        27
        upper Limit
        137
        value
        89
denoms
  1. counts
    1. group Id
      OG000
      value
      16
    2. group Id
      OG001
      value
      9
    units
    Participants
description
Disease-free survival is defined as participants who are still alive and without disease at study completion. Study completion was either death or completion of all protocol-specified activities, whichever came first.
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients receive veliparib PO BID on days 1-21 and topotecan hydrochloride IV continuously over 24 hours and carboplatin IV continuously over 24 hours on days 3-7. Treatment repeats every 28-63 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
    id
    OG000
    title
    Arm A (Veliparib, Topotecan Hydrochloride, Carboplatin)
  2. description
    Patients receive topotecan hydrochloride IV continuously over 24 hours and carboplatin IV continuously over 24 hours on days 1-5. Treatment repeats every 28-63 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
    id
    OG001
    title
    Arm B (Topotecan Hydrochloride, Carboplatin)
param Type
MEDIAN
reporting Status
POSTED
time Frame
Up to 7 months
title
Duration of Disease-free Survival
type
SECONDARY
unit Of Measure
days

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice